Comparison of the effects of moxibustion and lipid-lowering drugs for primary hyperlipidemia:a meta-analysis

• 作者: Bao-Jie Han Sheng-Nan Song Si-Yu Liu Wei Xu Yan-Ru Xia Yan-Zuo Liu
• 来源期刊: TMR非药物治疗
• 学科: 医学
• 关键词: MOXIBUSTION HYPERLIPEMIA META-ANALYSIS RANDOMIZED CONTROLLED TRIAL
• 年，卷（期）: 2019,（3）
• 页码范围: 85-94
• 页数: 10页
• 分类号: R

摘要

Objective:Systematically compared the effects of moxibustion and lipid-lowering drugs on hyperlipemia.Methods:Randomized controlled trials(RCTs)published before December 2018 were all aggregated,focusing on evaluation of moxibustion and lipid-lowering drugs for hyperlipemia from PubMed,EMbase,the Cochrane Library,Web of Science,CNKI,CBM,WANFANG database and VIP databases.The quality of the included studies was assessed basing on Cochrane handbook 5.1.0,and the available data were analyzed with RevMan software(version 5.3).Results:Totally 8 RCTs were included with 561 patients.Compared with statins,moxibustion had a better effect to reduce the total cholesterol(TC)(MD=-0.19,95%CI:-0.24,0.13,P<0.001).Moxibustion also had a better effect to reduce low density lipoprotein cholesterol(LDL-C)in compared with statins and fibrates(MD=0.20,95%CI:0.15,-0.25,P<0.001),but there were no significant differences between statins,fibrates and moxibustion in lowering triglyceride(TG)(MD=-0.02,95%CI:-0.09,0.05,P=0.61)and High-density lipoprotein cholesterol(HDL-C)(MD=0.03,95%CI:0.06,0.13,P=0.51).While,compared with the Chinese patent medicine,there was no significant difference in the efficacy of lowering TC(MD=0.05,95%CI:0.17,0.27,P=0.67),TG(MD=-0.08,95%CI:0.41,0.24,P=0.61),LDL-C(MD=-0.14,95%CI:0.38,0.11,P=0.28)and HDL-C(MD=0.11,95%CI:0.01,0.22,P=0.06).Conclusion:Compared with statins and fibrates,moxibustion had advantages in lowering TC and LDL-C,but there was no robust evidence that moxibustion was superior to Chinese patent medicine in improving the blood lipid indexes of patients with hyperlipidemia.